Dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to chemotherapy treated with pegfilgrastim

Trial Profile

Dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to chemotherapy treated with pegfilgrastim

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 May 2017

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Febrile neutropenia
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 25 May 2017 Recruitment is completed according to results published in the Wiener Klinische Wochenschrift
    • 25 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top